Li J J, Li S A
Division of Etiology and Prevention of Hormonal Cancers, University of Kansas Cancer Center, Kansas City 66160-7312, USA.
Prog Clin Biol Res. 1996;394:255-67.
It is proposed that the kidney cytotoxicity or tubular damage and the subsequent regenerative cell proliferation elicited by estrogens after chronic hormone treatment is driven specifically by the intrinsic estrogenic property of these agents. The sequence of events leading to estrogen-induced renal tumorigenesis in the hamster is presented in Figure 2. There are a number of events that occur rapidly and nearly simultaneously. First, there is an alteration in kidney proximal tubule (PCT) cells that is manifested by an elevation in both ER and PR at about 1.5 and 3 months, respectively. This clearly demonstrates an increased responsiveness of the kidney tubule to estrogen. Second, there is a progressive PCT cytotoxicity or cell injury, occurring as early as 1.5 months, which increases in severity with continued estrogen exposure. Initially, when the tubular damage is not severe, the reparative hyperplasia occurs mainly in the mature proximal tubules. Third, with increased severity in renal tubular cell damage, committed epithelial interstitial stem cell populations, shown to be the origin of this tumor, begin to proliferate in an effort to repair the increasing cell damage induced by chronic estrogen treatment. As a consequence of this regenerative cell proliferation, in both mature proximal tubules (limited) and primitive interstitial stem cells, aneuploid cells in both dividing mature and primitive kidney cells are significantly elevated. This view is consistent with the specific estrogen-induced cell proliferation in culture cited earlier. Evidence has recently been provided in our laboratory that suggests that chromosomal instability as a result of nonrandom chromosomal alterations (trisomies, tetrasomies, monosomies) as well as other chromosomal aberrations contribute critically to early events in renal tumorigenesis in the hamster. Moreover, overexpression of protooncogenes and suppressor genes occurs as early as 4 months of estrogen treatment. Therefore, the nongenotoxic estrogen-induced neoplastic transformation in the hamster kidney is suggested to occur in a series of discrete molecular events that is now believed to be primarily hormonally driven and hormonally dependent.
有人提出,慢性激素治疗后雌激素引发的肾细胞毒性或肾小管损伤以及随后的再生细胞增殖,是由这些药物固有的雌激素特性特异性驱动的。导致仓鼠雌激素诱导肾肿瘤发生的事件序列如图2所示。有许多事件迅速且几乎同时发生。首先,肾近端小管(PCT)细胞发生改变,分别在约1.5个月和3个月时表现为雌激素受体(ER)和孕激素受体(PR)升高。这清楚地表明肾小管对雌激素的反应性增加。其次,早在1.5个月时就出现了进行性的PCT细胞毒性或细胞损伤,随着雌激素持续暴露,损伤严重程度增加。最初,当肾小管损伤不严重时,修复性增生主要发生在成熟的近端小管。第三,随着肾小管细胞损伤严重程度的增加,已证明是这种肿瘤起源的定向上皮间质干细胞群开始增殖,以修复慢性雌激素治疗引起的不断增加的细胞损伤。由于这种再生细胞增殖,在成熟近端小管(有限)和原始间质干细胞中,分裂的成熟和原始肾细胞中的非整倍体细胞显著增加。这一观点与前面提到的培养中雌激素诱导的特异性细胞增殖一致。最近我们实验室提供的证据表明,非随机染色体改变(三体、四体、单体)以及其他染色体畸变导致的染色体不稳定性对仓鼠肾肿瘤发生的早期事件起关键作用。此外,早在雌激素治疗4个月时就出现了原癌基因和抑癌基因的过表达。因此,推测仓鼠肾中无基因毒性的雌激素诱导的肿瘤转化发生在一系列离散的分子事件中,现在认为这些事件主要由激素驱动且依赖于激素。